[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361081-105":59,"doc-detail-361081-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","advancements-in-understanding-and-treating-cxcl16cxcr6-in-tumors-and-in-inflammatory-diseases-a-narrative-review","Advancements in understanding and treating CXCL16/CXCR6 in tumors and in inflammatory diseases - a narrative review","","The CXCL16/CXCR6 axis shows multifaceted, bidirectional control across neoplasms and inflammatory conditions, acting as both an inhibitor and a facilitator of disease progression depending on context. This narrative review systematically maps the axis’ functional spectrum across tumor microenvironment regulation and inflammatory diseases, highlighting how tumor heterogeneity and CXCL16 isoforms (membrane-bound versus soluble) shape outcomes. It also evaluates predictive value, emerging asthma-related evidence, and current drug-development advances, emphasizing the importance of defining critical functional nodes for targeted therapy.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advancements-in-understanding-and-treating-cxcl16cxcr6-in-tumors-and-in-inflammatory-diseases-a-narrative-review/361081/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advancements-in-understanding-and-treating-cxcl16cxcr6-in-tumors-and-in-inflammatory-diseases-a-narrative-review/361081.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why is the CXCL16/CXCR6 axis described as “double-edged” in diseases?","Question",{"text":112,"@type":113},"Its regulatory influence can inhibit or promote disease progression depending on the biological context. The review emphasizes this bidirectional, context-dependent behavior across tumors and inflammatory disorders.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do CXCL16 isoforms influence outcomes in the tumor microenvironment?",{"text":117,"@type":113},"Tumor heterogeneity and CXCL16 isoforms—membrane-bound (mCXCL16) versus soluble (sCXCL16)—are highlighted as key determinants of functional effects. The review discusses how these forms contribute differently to regulatory mechanisms.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the role of CXCL16/CXCR6 in inflammatory diseases such as asthma?",{"text":121,"@type":113},"The review broadens from tumors to inflammatory diseases by examining the axis’ potential as a predictive marker and summarizing latest insights into its involvement in conditions including asthma.",{"name":123,"@type":110,"acceptedAnswer":124},"What is the main challenge and opportunity for developing targeted therapies against this axis?",{"text":125,"@type":113},"Accurately identifying the critical nodes where the CXCL16/CXCR6 axis changes its function is presented as the central challenge and opportunity for targeted therapy development.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},361081,1790592716,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","TYPE Review  \nPUBLISHED 20 July 2026  \nDOI 10.3389/fimmu.2026.1802735  \nOPEN ACCESS  \nEDITED BY  \nPriscilla Brebi,  \nUniversity of La Frontera, Chile  \nREVIEWED BY  \nMd Sadique Hussain, Uttaranchal University, India Jiaqi Wang,  \nGannan Medical University, China  \n*CORRESPONDENCE  \nChunping Wan  \n[wanchunping1012@163.com](wanchunping1012@163.com)  \n†These authors have contributed equally to this work  \nRECEIVED 03 February 2026  \nREVISED 02 March 2026  \nACCEPTED 06 March 2026  \nPUBLISHED 20 July 2026  \nCITATION  \nLi X, Liu S, Qian D, Huang M, Na M, Mo Q, Ju M, Ge J, Gao J, Zhang X and Wan C (2026) Advancements in understanding and treating CXCL16/ CXCR6 in tumors and in inﬂammatory diseases: a narrative review.  \nFront. Immunol. 17:1802735 .  \ndoi: 10.3389/fimmu.2026.1802735  \nCOPYRIGHT  \n© 2026 Li, Liu, Qian, Huang, Na, Mo, Ju, Ge, Gao, Zhang and Wan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAdvancements in understanding and treating CXCL16/CXCR6 in tumors and in inﬂammatory diseases: a narrative review  \nXiaohong Li 1,2†, Shuai Liu 1†, Die Qian 1,2†, Maokui Huang 1, Mingmin Na 1, Qingyan Mo 1, Mingqian Ju 1, Jingjing Ge 1, Jie Gao 1, Xueling Zhang 1 and Chunping Wan 1,2*  \n1 First Clinical Medical College, School of Pharmacy and School of Basic Medicine, Yunnan University of Chinese Medicine, Kunming, China, 2 Department of Scientiﬁc Research, The Fifth Afﬁliated Hospital of Yunnan University of Chinese Medicine, Chuxiong, China  \nThe CXCL16/CXCR6 axis exerts a multifaceted, bidirectional regulatory inﬂuenceacross various pathological processes, including neoplasms and inﬂammatory disorders. Its functions are notably context-dependent, possessing the capacity to both inhibit and facilitate disease progression. This article aims to systematically analyze this ‘double-edged sword ’ characteristic by providing an exhaustive review of the axis ’s functional spectrum across different diseases. Initially, we explore its bidirectional regulatory mechanisms within the tumor microenvironment, emphasizing the inﬂuence of tumor heterogeneity and the distinct roles of CXCL16 isoforms (membrane-bound and soluble) in determining functional outcomes. Subsequently, we broaden the discussion to encompass inﬂammatory diseases, examining the axis ’s potential as a predictive marker in these conditions and presenting the latest insights into its role in diseases such as asthma. Additionally, we provide a review of current advancements in drug development targeting this axis and elucidate its mechanisms of action . Ultimately, the paper underscores that accurately identifying the critical nodes where the CXCL16/CXCR6 axis alters its function is the central challenge and opportunity for the development of targeted therapies.  \nKEYWORDS  \nCXCL16, CXCR6, inﬂammation, tumor, tumor microenvironment  \n1 Introduction  \nThe CXC chemokine family includes CXCL16, which was discovered by Matloubianet [al. in 2000](al. in 2000) (1). A major member of the CXC chemokine family, consisting of 254 amino acids (2) . It is described as a divergent CXC chemokine due to its atypical features among CXC chemokines (3) . This formation might lead to distinct structural and functional characteristics. There are three forms present, namely membrane-bound CXCL16 (mCXCL16), soluble CXCL16 (sCXCL16) and CXCL16v (4) . mCXCL16 functions as an adhesion molecule, binding to CXCR6-expressing cells and facilitating cell-to-cell interactions. It mediates cell adhesion and the uptake of oxidized lipoproteins. In an inﬂammatory milieu, cleavage of mCXCL16 by disintegrin and meta","cbCaihaAEFfoNhNT","https://ap.wps.com/l/cbCaihaAEFfoNhNT","pdf",2819476,17,"English","# Introduction\n## CXCL16 and CXCR6 biology and forms\n# Bidirectional regulation in the tumor microenvironment\n## Tumor heterogeneity and CXCL16 isoforms\n# Roles in inflammatory diseases\n## Predictive marker potential and asthma insights\n# Therapeutic targeting and drug development","[{\"question\":\"Why is the CXCL16/CXCR6 axis described as “double-edged” in diseases?\",\"answer\":\"Its regulatory influence can inhibit or promote disease progression depending on the biological context. The review emphasizes this bidirectional, context-dependent behavior across tumors and inflammatory disorders.\"},{\"question\":\"How do CXCL16 isoforms influence outcomes in the tumor microenvironment?\",\"answer\":\"Tumor heterogeneity and CXCL16 isoforms—membrane-bound (mCXCL16) versus soluble (sCXCL16)—are highlighted as key determinants of functional effects. The review discusses how these forms contribute differently to regulatory mechanisms.\"},{\"question\":\"What is the role of CXCL16/CXCR6 in inflammatory diseases such as asthma?\",\"answer\":\"The review broadens from tumors to inflammatory diseases by examining the axis’ potential as a predictive marker and summarizing latest insights into its involvement in conditions including asthma.\"},{\"question\":\"What is the main challenge and opportunity for developing targeted therapies against this axis?\",\"answer\":\"Accurately identifying the critical nodes where the CXCL16/CXCR6 axis changes its function is presented as the central challenge and opportunity for targeted therapy development.\"}]","Advancements in understanding and treating CXCL16/CXCR6 in tumors and in inflammatory diseases - a narrative review | PDF",1790143053,43,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/209dfc15281ecce9f73199aa9ea60d15.webp",983,1389,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53333f146e13d7174328b077e3d9cf24.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13a2be2f19262a9b0ce6ee47ea3d5af1.webp",981,1386,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f54776d812901d95ec2fb669275cf852.webp",980,1385]